FDA Issues Import Alert 45-02, Impacting Anhui Company

Recently, the U.S. Food and Drug Administration (FDA) released an updated import alert on its official website, implementing automatic detention for products from a certain company in China. Specific information is as follows:

• Alert Number: 45-02
• Release Date: January 2, 2025
• Region: Ma'anshan, Anhui
• Company Name: Sirio Healthcare (Anhui) Co., Ltd
• Product Name: Compound Vitamin Pectin Gummies
• Testing Item: Copper Chlorophyllin Sodium Salt

Import alerts are a preventive measure taken by the FDA for imported foods that pose potential risks. For companies or products included in the import alert scope, the FDA will implement Detention Without Physical Examination (DWPE) measures. It is important to clarify that automatic detention does not equate to the product failing to meet U.S. import standards. Goods that are automatically detained must pass inspection by the FDA or an FDA-recognized laboratory and receive approval from the local FDA branch before customs will release them, allowing them to enter the U.S. market for sale.

This serves as a reminder to related exporting companies to strictly adhere to the relevant requirements of the importing country, ensuring the safety and compliance of exported food and related products to avoid the risk of detention during the import process.